Patents by Inventor Ronald D. Schoenwald

Ronald D. Schoenwald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lacrimal secretion stimulant (lss)
    Patent number: 4820737
    Abstract: Ophthalmic compositions useful as tear stimulants when topically applied to the eye for effective treatment of dry eye syndrome.
    Type: Grant
    Filed: March 16, 1988
    Date of Patent: April 11, 1989
    Assignee: University of Iowa Research Foundation
    Inventors: Ronald D. Schoenwald, Charles F. Barfknecht
  • Controlled release ophthalmic gel formulation
    Patent number: 4738851
    Abstract: An ophthalmic gel for topical application to the conjunctival sac of the eye. The gel comprises an ophthalmic drug carried in a gel which provides good ocular retention while avoiding burst release of medicament and yet at the same time providing controlled release of the medicament. The gel contains in combination sodium carboxymethyl-cellulose and colloidal magnesium aluminum silicate. A combination of these ingredients in the gel provides the desired effects.
    Type: Grant
    Filed: June 12, 1986
    Date of Patent: April 19, 1988
    Assignee: University of Iowa Research Foundation, Inc.
    Inventors: Ronald D. Schoenwald, John L. Lach
  • Phenylephrine prodrug useful as mydriatic agent
    Patent number: 4705798
    Abstract: An oxazolidine derivative of phenylephrine, and the non-toxic pharmaceuticlaly acceptable salt forms thereof. The prodrug is much quicker absorbed across the cornea of the eye, does not induce the same unwanted side effects as phenylephrine, and can produce the same mydriatic effect as phenylephrine at dosage levels of approximately one-tenth the level of phenylephrine.
    Type: Grant
    Filed: September 27, 1985
    Date of Patent: November 10, 1987
    Assignee: University of Iowa Research Foundation
    Inventors: Ronald D. Schoenwald, Du-Shieng Chien
  • Non-classical topical treatment for glaucoma
    Patent number: 4636515
    Abstract: A topical composition for eye treatment of glaucoma, comprising a small but pharmaceutically effective amount of a non-classical carbonic anhydrase inhibitor. The most preferred compound is methyl acetazolamide. The invention also relates to a method of topically treating glaucoma with eye drops of a non-classical carbonic anhydrase inhibitor to reduce intraocular pressure.
    Type: Grant
    Filed: June 25, 1984
    Date of Patent: January 13, 1987
    Assignee: University of Iowa Research Foundation
    Inventors: Charles F. Barfknecht, Ronald D. Schoenwald
  • Non-classical topical treatment for glaucoma
    Patent number: 4629738
    Abstract: A topical composition for eye treatment of glaucoma, comprising a small but pharmaceutically effective amount of a non-classical carbonic anhydrase inhibitor. The most preferred compound is methyl acetazolamide. The invention also relates to a method of topically treating glaucoma with eye drops of a non-classical carbonic anhydrase inhibitor to reduce intraocular pressure.
    Type: Grant
    Filed: June 25, 1984
    Date of Patent: December 16, 1986
    Assignee: University of Iowa Research Foundation
    Inventors: Charles F. Barfknecht, Ronald D. Schoenwald
  • Oil suspended phenylephrine
    Patent number: 4623664
    Abstract: An oil suspension, preferably sesame seed oil suspension, of the base form of phenylephrine as an opthalmic medicament. Surprisingly, the base form of phenylephrine is much quicker absorbed into the eye than the conventional acid salt form. As a result, lower dosage levels can be used to achieve the same mydriatic effect, thus reducing the risk of adverse side effects from systemic absorption.
    Type: Grant
    Filed: October 31, 1985
    Date of Patent: November 18, 1986
    Assignee: University of Iowa Research Foundation
    Inventors: Ronald D. Schoenwald, Du-Shieng Chien
  • Non-classical topical treatment for glaucoma
    Patent number: 4483864
    Abstract: A topical composition for eye treatment of glaucoma, comprising a small but pharmaceutically effective amount of a non-classical carbonic anhydrase inhibitor. The most preferred compound is methyl acetazolamide. The invention also relates to a method of topically treating glaucoma with eye drops of a non-classical carbonic anhydrase inhibitor to reduce intraocular pressure.
    Type: Grant
    Filed: February 4, 1983
    Date of Patent: November 20, 1984
    Assignee: University of Iowa Research Foundation
    Inventors: Charles F. Barfknecht, Ronald D. Schoenwald
  • Non-classical topical treatment for glaucoma using n-substituted sulfonamides
    Patent number: 4483872
    Abstract: A topical composition for eye treatment of glaucoma, comprising a small but pharmaceutically effective amount of a non-classical carbonic anhydrase inhibitor. The most preferred compound is methyl acetazolamide. The invention also relates to a method of topically treating glaucoma with eye drops of a non-classical carbonic anhydrase inhibitor to reduce intraocular pressure.
    Type: Grant
    Filed: July 11, 1983
    Date of Patent: November 20, 1984
    Assignee: University of Iowa Research Foundation
    Inventors: Charles F. Barfknecht, Ronald D. Schoenwald
  • Sustained release ophthalmic drug dosage
    Patent number: 4407792
    Abstract: The present invention is directed to an aqueous dispersion of an ophthalmic drug and a high molecular weight polymer which forms a highly viscous gel and can be used to prolong the duration of activity of the ophthalmic drug when the gel is applied into the conjunctival sac of the eye. The ophthalmic drug-containing gel composition has prolonged retention time in the eye and remains in contact with the surface of the eye for an extended period of time.
    Type: Grant
    Filed: March 12, 1981
    Date of Patent: October 4, 1983
    Assignee: Alcon Laboratories, Inc.
    Inventors: Ronald D. Schoenwald, Robert E. Roehrs
  • Sustained release ophthalmic drug dosage
    Patent number: 4271143
    Abstract: The present invention is directed to an aqueous dispersion of an ophthalmic drug and a high molecular weight polymer which forms a highly viscous gel and can be used to prolong the duration of activity of the ophthalmic drug when the gel is applied into the conjunctival sac of the eye. The ophthalmic drug-containing gel composition has prolonged retention time in the eye and remains in contact with the surface of the eye for an extended period of time.
    Type: Grant
    Filed: May 9, 1979
    Date of Patent: June 2, 1981
    Assignee: Alcon Laboratories, Inc.
    Inventors: Ronald D. Schoenwald, Robert E. Roehrs